Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

Urology. 1985 Feb;25(2):119-23. doi: 10.1016/0090-4295(85)90525-4.

Abstract

Between March, 1978, and July, 1981, 86 patients with polychronotopic superficial papillary bladder tumors and concurrent carcinoma in situ were randomized to receive either transurethral resection alone (43) or TUR plus BCG (43). The results indicate that BCG is not only active in preventing recurrences of new tumors but also effective for the diffuse, flat carcinoma in situ.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • BCG Vaccine / therapeutic use*
  • Biopsy
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / surgery
  • Carcinoma in Situ / therapy*
  • Carcinoma, Papillary / pathology
  • Carcinoma, Papillary / surgery
  • Carcinoma, Papillary / therapy*
  • Clinical Trials as Topic
  • Electrosurgery
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / therapy*
  • Random Allocation
  • Time Factors
  • Urinary Bladder / pathology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*

Substances

  • BCG Vaccine